older patientBruton tyrosine kinaseBCL2cost-effectivenessBruton tyrosine kinase inhibitors (BTKi) and the BCL2 inhibitor venetoclax, with or without the anti-CD20 monoclonal antibody Obinutuzumab, represent the preferred options for the first-line therapy of CLL because they are more effective and may...
CLL: Ibrutinib holds promise for first-line treatment of older patientsA Phase II trial of previously untreated, symptomatic CLL patients over 65, reported at ASCO, found that iibrutinib dramatically improved one-year response and survival data....
The introduction of 12-month fixed duration venetoclax plus obinutuzumab as first-line treatment for chronic lymphocytic leukaemia (CLL) under a US health plan is associated with cost savings compared to treatment plans involving chemoimmunotherapies and ibrutinib-based therapies only, according to a ...
Chronic lymphocytic leukemia (CLL) exhibits a highly variable natural history, but the addition of genomic risk stratification to traditional clinical staging systems has begun to explain the heterogeneous clinical course. Overall response to treatment has significantly improved over the past three decades...
Sequencing Treatment in R/R CLL: CAR T-Cell Therapy vs Pirtobrutinib in Double-Exposed Patients Weighing CAR T Toxicity Profiles in Early R/R MM CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 TrialRelated Content View More OncLive Peer Exchange® Lung Cancer February...
In first-line therapy of chronic lymphocytic leukemia (CLL), alemtuzumab (Campath) has superior efficacy to the standard treatment, oral chlorambucil, with manageable toxicity, according to results of the CAM307 trial. ORLANDOIn first-line therapy of chronic lymphocytic leukemia (C...
Introduction : Ibr+Ven is an all-oral, chemotherapy-free, FD treatment option that provides a deep and durable response for treatment-naive (TN) pts with CLL. In the phase 3 GLOW trial, FD Ibr+Ven significantly prolonged OS versus chemoimmunotherapy in pts with TN CLL. With a median follo...
Longer PFS and Manageable Toxicity With First-Line Alemtuzumab vs Chlorambucil in Patients With CLL Dental Preclearance and Careful Tracking Can Prevent Osteonecrosis of the Jaw Due to Bisphosphonates Medicare Fee Poor Proxy in Economic Analyses of Mammography ...
On December 25, 2020, obutinib was approved by nmpa for the treatment of relapsed / refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) patients and relapsed / refractory MCL patients. On December 31, 2020, obutinib was awarded orphan drug designation by the US ...
The mean age at diagnosis of chronic lymphocytic leukemia (CLL) is 72 years, with 22.8% of patients being older than 80 years. However, the elderly are underrepresented in clinical studies of CLL. We performed a retrospective study of CLL patients aged 80 years or older at the initiation of...